At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 290 enrolled
Drug / intervention
natalizumab IV +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis
In Brief
A Phase 2 clinical trial evaluating natalizumab IV, natalizumab SC, and 2 other interventions for Relapsing-Remitting Multiple Sclerosis. Completed, enrolled 290 participants across 64 sites in 5 countries.
Detailed Summary
The primary objective of this study is to explore the effects of multiple regimens of natalizumab on disease activity and safety in participants with relapsing-remitting Multiple Sclerosis (RRMS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing-Remitting Multiple Sclerosis
CountriesBelgium, France, Germany, Italy, Spain
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2011
Enrollment StartAug 2011
Primary CompletionApr 2014
Study CompletionOct 2014
TodayJul 2026
First PostedJul 29, 2011
Enrollment StartAug 1, 2011
Primary CompletionApr 1, 2014
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 14.9 years ago
Interventions
natalizumab IVdrug
natalizumab for IV Infusion
natalizumab SCdrug
natalizumab for Subcutaneous Injection
IV Placebodrug
Intravenous placebo to natalizumab
SC Placebodrug
Subcutaneous placebo to natalizumab